Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease

Brain Research

Volumn 1068, Issue 1, 2006, Pages 230-236

  Sharma, Rohita ^a   McMillan, Catherine R ^a   Tenn, Catherine C ^b,c   Niles, Lennard P ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

Author keywords

Brain derived neurotrophic factor; Contralateral compensation; Glial cell line derived neurotrophic factor; Partial lesion; Striatum; Tyrosine Hydroxylase

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MELATONIN; MESSENGER RNA; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

ANIMALS; APOMORPHINE; BRAIN-DERIVED NEUROTROPHIC FACTOR; DENSITOMETRY; DOPAMINE AGONISTS; FUNCTIONAL LATERALITY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IMMUNOHISTOCHEMISTRY; MALE; MELATONIN; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MELATONIN, MT1; RECEPTORS, MELATONIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEREOTYPED BEHAVIOR; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; PARKINSONIA;

EID: 31344477300     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2005.10.084     Document Type: Article

References (30)

1. M.A. Ariano, N. Aronin, M. Difiglia, D.A. Tagle, D.R. Sibley, B.R. Leavitt, M.R. Hayden, and M.S. Levine Striatal neurochemical changes in transgenic models of Huntington's disease J. Neurosci. Res. 68 2002 716 729
2. K.J. Armstrong, and L.P. Niles Induction of GDNF mRNA expression by melatonin in rat C6 glioma cells NeuroReport 13 2002 473 475
3. V. Blanchard, M. Chritin, S. Vyas, M. Savasta, C. Feuerstein, Y. Agid, F. Javoy-Agid, and R. Raisman-Vozari Long-term induction of tyrosine hydroxylase expression: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain J. Neurochem. 64 1995 1669 1679
4. V. Blanchard, P. Anglade, G. Dziewczapolski, M. Savasta, Y. Agid, and R. Raisman-Vozari Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra Brain Res. 709 1996 319 325
5. F. Dabbeni-Sala, S. Di Santo, D. Franceschini, S.D. Skaper, and P. Giusti Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity FASEB J. 15 2001 164 170
6. B. Georgievska, D. Kirik, and A. Bjorklund Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer Exp. Neurol. 177 2002 461 474
7. S.S. Gill, N.K. Patel, G.R. Hotton, K. O'Sullivan, R. McCarter, M. Bunnage, D.J. Brooks, C.N. Svendsen, and P. Heywood Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nat. Med. 9 2003 589 595
8. J. He, S.W. Hoffman, and D.G. Stein Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury Restor. Neurol. Neurosci. 22 2004 19 31
9. C. Jollivet, A. Aubert-Pouessel, A. Clavreul, M.C. Venier-Julienne, S. Remy, C.N. Montero-Menei, J.P. Benoit, and P. Menei Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease Biomaterials 25 2004 933 942
10. W.S. Joo, B.K. Jin, C.W. Park, S.H. Maeng, and Y.S. Kim Melatonin increases striatal dopaminergic function in 6-OHDA-lesioned rats NeuroReport 9 1998 4123 4126
11. D. Kirik, B. Georgievska, and A. Bjorklund Localized striatal delivery of GDNF as a treatment for Parkinson disease Nat. Neurosci. 7 2004 105 110
12. D.A. Kozlowski, E.A. Miljan, E.G. Bremer, C.G. Harrod, C. Gerin, B. Connor, D. George, B. Larson, and M.C. Bohn Quantitative analyses of GFRalpha-1 and GFRalpha-2 mRNAs and tyrosine hydroxylase protein in the nigrostriatal system reveal bilateral compensatory changes following unilateral 6-OHDA lesions in the rat Brain Res. 1016 2004 170 181
13. J. Leon, D. Acuna-Castroviejo, G. Escames, D.X. Tan, and R.J. Reiter Melatonin mitigates mitochondrial malfunction J. Pineal Res. 38 2005 1 9
14. M.M. Macchi, and J.N. Bruce Human pineal physiology and functional significance of melatonin Front. Neuroendocrinol. 25 2004 177 195
15. J.C. Mayo, R.M. Sainz, D.X. Tan, I. Antolin, C. Rodriguez, and R.J. Reiter Melatonin and Parkinson's disease Endocrine 27 2005 169 178
16. L.P. Niles, and K.J. Armstrong Modulation of GDNF expression by melatonin Soc. Neurosci. 2002 (Abstract, Program No. 691.2 Online)
17. S.P. Onn, T.W. Berger, E.M. Stricker, and M.J. Zigmond Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: histochemical and neurochemical analysis Brain Res. 376 1986 8 19
18. R.J. Reiter, R.X. Tan, and M.A. Pappolla Melatonin relieves the neural oxidative burden that contributes to dementias Ann. N. Y. Acad. Sci. 1035 2004 179 196
19. C. Rodriguez, J.C. Mayo, R.M. Sainz, I. Antolin, F. Herrera, V. Martin, and R.J. Reiter Regulation of antioxidant enzymes: a significant role for melatonin J. Pineal Res. 36 2004 1 9
20. D.C. Skinner, and B. Malpaux High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus Endocrinology 140 1999 4399 4405
21. A.D. Smith, D.A. Kozlowski, M.C. Bohn, and M.J. Zigmond Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats Exp. Neurol. 193 2005 420 426
22. C.C. Tenn, and L.P. Niles Central-type benzodiazepine receptors mediate the antidopaminergic effect of clonazepam and melatonin in 6-hydroxydopamine lesioned rats: involvement of a GABAergic mechanism J. Pharmacol Exp. Ther. 1 1995 84 89
23. C.C. Tenn, and L.P. Niles Modulation of dopaminergic activity in the striatum by benzodiazepines and melatonin Pharmacol. Rev. Commun. 12 2002 171 178
24. B. Thomas, and K.P. Mohanakumar Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum J. Pineal Res. 36 2004 25 32
25. T. Uz, M. Akhisaroglu, R. Ahmed, and H. Manev The pineal gland is critical for circadian Period1 expression in the striatum and for circadian cocaine sensitization in mice Neuropsychopharmacology 12 2003 2117 2123
26. I. Vega-Naredo, B. Poeggeler, V. Sierra-Sanchez, B. Caballero, C. Tomas-Zapico, O. Alvarez-Garcia, D. Tolivia, M.J. Rodriguez-Colunga, and A. Coto-Montes Melatonin neutralizes neurotoxicity induced by quinolinic acid in brain tissue culture J. Pineal Res. 39 2005 266 275
27. C. Von Gall, D.R. Weaver, J. Moek, A. Jilg, J.H. Stehle, and H.W. Korf Melatonin plays a crucial role in the regulation of rhythmic clock gene expression in the mouse pars tuberalis Ann. N. Y. Acad. Sci. 1040 2005 508 511
28. T. Wolden-Hanson, D.R. Mitton, R.L. McCants, S.M. Yellon, C.W. Wilkinson, A.M. Matsumoto, and D.D. Rasmussen Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat Endocrinology 141 2000 487 497
29. S.S. Wu, and S.J. Frucht Treatment of Parkinson's disease: what's on the horizon? CNS Drugs 19 2005 723 743
30. H. Xiao, Y. Hirata, K. Isobe, and K. Kiuchi Glial cell line-derived neurotrophic factor up-regulates the expression of tyrosine hydroxylase gene in human neuroblastoma cell lines J. Neurochem. 82 2002 801 808